Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546258 | 0.83 | ERN1 (0.39) | ALDH1A1TRPA1ACHEPTGS1PTGS2 | |
| SCHEMBL22133772 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TRPA1ACHEPTGS1PTGS2 | |
| SCHEMBL27396426 | 0.79 | TRPA1 (0.39) | ALDH1A1TRPA1ACHEPTGS1PTGS2 | |
| SCHEMBL12463870 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TRPA1CYP1A2ACHEPTGS1 | |
| SCHEMBL22133743 | 0.79 | CA6 (0.39) | ALDH1A1TRPA1CA3CA6CA5A | |
| SCHEMBL29407125 | 0.77 | ALDH1A1 (0.53) | ALDH1A1TRPA1CYP1A2GABRA1GABRB2 | |
| SCHEMBL23915 | 0.77 | ALDH1A1 (0.53) | ALDH1A1TRPA1CYP1A2GABRA1GABRB2 | |
| SCHEMBL15485256 | 0.77 | ALDH1A1 (0.53) | ALDH1A1TRPA1CYP1A2GABRA1GABRB2 | |
| SCHEMBL25370491 | 0.75 | ALDH1A1 (0.40) | ALDH1A1TRPA1CYP1A2ACHEPTGS1 | |
| SCHEMBL22699000 | 0.75 | ALDH1A1 (0.36) | ALDH1A1CA3CA6CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
| EP-3904294-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| CN-110041253-A | Pyridines N- oxidized derivatives and its preparation method and application | 上海翰森生物医药科技有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-109836385-A | Tetrahydro chinolines N- oxidized derivatives and its preparation method and application | 上海翰森生物医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2240482-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009095162-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, PM20D2, CDK20 | ALDH1A1 2609/4885TRPA1 3730/4885CYP1A2 117/4885 |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | ALDH1A1 1881/4885TRPA1 3592/4885CYP1A2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.